Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT06307509 |
| Other study ID # |
GN23AN097 |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
March 2024 |
| Est. completion date |
July 31, 2025 |
Study information
| Verified date |
March 2024 |
| Source |
NHS Greater Glasgow and Clyde |
| Contact |
Malcolm AB Sim, MBChB, MD |
| Phone |
+44(0)1412112470 |
| Email |
Malcolm.Sim[@]ggc.scot.nhs.uk |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Obesity has been shown to increase adverse outcomes in some critically ill patients e.g.
those with COVID-19. For patients with sepsis this association is less clear cut but there is
evidence that body fat distribution, resulting from impaired subcutaneous adipose tissue
function, is associated with adverse clinical outcomes in critical care. The investigators
aim to study subcutaneous adipose tissue function in lean and obese sepsis patients in
critical care and compare that to healthy controls.
First, the study will investigate differences in adipose tissue function (inflammation and
mitochondrial function) related to obesity. Second, the investigators will examine whether
lean critically ill patients with sepsis have enhanced adipose tissue inflammation and
mitochondrial dysfunction compared to lean controls and whether this is further exacerbated
by obesity.
Patients will be either undergoing emergency abdominal surgery, or will have been admitted to
a critical care unit with a diagnosis of sepsis.
The investigators will collect blood and adipose tissue biopsies from the patients, and these
will be analysed for markers of inflammation and of mitochondrial function.
The aim is to better understand the relationship between obesity, inflammation, mitochondrial
dysfunction and sepsis. The investigators hope that this may improve the understanding of the
pathophysiology of sepsis and allow more targeted interventions for patients based on
differences in their baseline metabolic state.
Description:
Hypothesis The hypothesis is that adipose tissue from patients who are critically ill with
sepsis will show changes in structure, increased inflammatory function, and increased
mitochondrial dysfunction in comparison to control patients without sepsis. The investigators
also hypothesise that that increased inflammatory function will be more pronounced in VAT
than in SAT.
Aims The investigators aim to investigate potential differences in adipose tissue structure,
inflammatory function, and mitochondrial dysfunction between individuals with and without
sepsis, and between SAT and VAT.
Study design
There will be two patient cohorts:
1. Patients undergoing emergency surgery with a diagnosis of sepsis
a. 15-30 patients
2. Patients admitted to a critical care unit with a diagnosis of sepsis
1. 15-30 patients
Results from patients with sepsis will be compared with results obtained from a
cohort of patients recruited to a previous study (CONNECT study: IRAS project ID
291251; REC reference 21/NS/0015). These patients are recruited when undergoing an
elective abdominal operation, with no evidence of an acute inflammatory process.
When recruited to the study, they undergo an identical fat and blood sampling
process to that described in this study.
Study Setting Patients will be recruited from the operating theatre suite and the
Critical Care Units at the Queen Elizabeth University Hospital Glasgow.
Adipose tissue samples will only be taken from those who require sedation or
general anaesthesia for tracheal intubation, either in the critical care unit, or
in the operating theatre.
Consent Consent process Patients in ICU, particularly in the acute phase of their
illness, often lack decision-making capacity due to delirium and the effects of
sedative medications. In order to evaluate the changes that take place in adipose
tissue during the acute phase of critical illness, it is important to undertake
sampling as soon as possible after a patient's admission to an ICU. It is
anticipated that the patients recruited in ICU in this study will not be able to
consent prospectively to enrolment in this study. Therefore, a researcher will seek
consent from a Welfare Attorney, Welfare Guardian or nearest relative. This
researcher will be trained in consent procedures that adhere to the ethical
principles in the Declaration of Helsinki and the Adults with Incapacity Act (2000)
Scotland. The researcher will provide the study Information Sheet, and the Consent
Form, and will review the contents to ensure that the procedures, benefits, and
risks of the study are understood. The person being approached will be asked to
give their consent based on their perception of the wishes of the patient if they
had capacity. They will then be invited to sign the consent form. The original will
be retained in the investigator site file, and a copy given to the person who
signed the form and another copy placed in the patients' medical records.
Patient consent to continue Patients consented to the study by a Welfare Attorney,
Welfare Guardian or nearest relative will be approached to obtain their permission
to continue in the study once they have recovered capacity after their critical
illness. Patients will be approached by an appropriately trained member of the
research team, and provided with the study Information Sheet, and a copy of the
Consent to Continue form. The researcher will review the contents of these with the
patient, provide clarification and an opportunity for questions. Patients who
decline to participate at this stage will be removed from the study.
Withdrawal from the study Participants may withdraw from the study at any point
without suffering any disadvantage.
Study procedures Clinical data collection
Baseline data will be collected for all patients recruited to the study. This will
include, but is not limited to:
- Age
- Sex
- BMI
- Major comorbidities
For patients admitted to an ICU, further data will be collected with regards to
their acute illness. This will include, but is not limited to:
- APACHE II
- Biochemical & haematological parameters, where measured clinically:
- Highest C-reactive protein in first 48 hours
- Highest white cell count in first 48 hours
- Highest procalcitonin in first 48 hours
- Highest lactate in first 48 hours
- Physiological parameters:
- Highest heart rate in first 48 hours (in beats per minute)
- Highest noradrenaline dose in first 48 hours (in mcg/min)
- Lowest P:F ratio in first 48 hours
- Highest dose of insulin delivered in first 48 hours (in units/hr)
- Outcome data:
- ICU length-of-stay
- ICU outcome
- Number of days requiring invasive mechanical ventilation
- Number of days requiring cardiovascular support
- Number of days requiring renal replacement therapy
- Hospital length-of stay
- Hospital outcome
Imaging data collection
The investigators will review the clinical imaging acquired for each patient
recruited into the study. Any patient who has undergone a CT scan, which includes
the L3 vertebral level, in the 12 months preceding their admission to an ICU, or
the 48 hours following their admission, will be suitable for CT-derived body
composition analysis. A single image slice at the level of the L3 vertebra will be
obtained. This image will then be deidentified and downloaded from PACS to an NHS
Greater Glasgow and Clyde computer. The deidentified image will then be uploaded to
the CoreSlicer software programme, and analysed as described previously (35). This
will allow calculation of the area of visceral adipose tissue, subcutaneous adipose
tissue, and muscle mass. This may provide a more nuanced assessment of an
individual's adiposity than BMI alone.
Blood and adipose tissue sampling Blood Sampling Up to 40ml of blood will be
collected by trained staff at recruitment to the study.
Adipose tissue sampling in patients in a critical care unit Adipose tissue will be
taken 5 cm lateral to the umbilicus under sterile conditions using a 20ml Terumo™
Luer Tip Syringe attached to a 14G 80mm Sterican Single Use Deep Intramuscular
Needle prefilled with approximately 5ml of 0.9% saline. Each biopsy pass collects
on average 0.3g tissue, so three passes should provide up to 1g adipose tissue.
This will be filtered through a 100μm nylon mesh filter and transported to the
laboratory in 15ml of pre-warmed (370C) Gibco™ Medium 199, Hanks' Balanced Salts
solution.
Adipose tissue sampling in patients undergoing emergency surgery Both subcutaneous
and visceral adipose tissue will be taken under direct vision by the surgical team.
Approximately 1g of tissue will be taken by from each site. This will be
transported to the laboratory in 15ml of pre-warmed (370C) Gibco™ Medium 199,
Hanks' Balanced Salts solution.
Transportation of samples to the University of Glasgow All samples (blood and
adipose tissue) will be packaged for transport to the University of Glasgow in
accordance with the current Health Protection Scotland guidance.
Expected duration of subject participation The whole procedure, including blood
sampling and adipose sampling, should take less than 30 minutes.
Adipose tissue analysis From a 1g adipose tissue biopsy, 300µl 90% cytocrit
adipocytes and a stromovascular fraction (SVF) can be prepared. If additional
adipose tissue is available, this will be flash frozen in liquid nitrogen and
stored at -800C for later histological analysis.
Adipocyte sizing will be carried out on unfixed fresh adipocyte suspensions (5µL)
isolated by collagenase digestion of the biopsy, imaged on an Olympus BX50
microscope using a x10 lens connected to 3-CCD colour camera (JVC) for digital
image capture with Image J automated sizing.
Basal and lipopolysaccharide (1µM) stimulated adipokine secretion, corrected for
cell number using adipocyte suspension DNA concentrations (isolated concurrently
with RNA), will be assessed in isolated adipocytes (in duplicate 50µL per assay)
after 2 hours at 37°C, as described previously (36).
Adipocyte inflammatory gene expression will be quantitated relative to the
endogenous control PPIA in RNA isolated from adipocyte suspension (95µL, yielding
approximately 500ng RNA) using TRIzol (ThermoFisher Scientific). Chosen targets
will be pre-amplified in the RNA followed by Taqman RT-PCR quantitation using
commercial primer probes sets (ThermoFisher Scientific).
SVF cells will be cultured in 25 cm2 flasks, in a 37°C 5% CO2 incubator, in
Dulbecco's Modified Eagle Medium (DMEM) and sampled at 2 and 24 hours for analysis
of cytokines. The culture (passage 0) will be continued to allow pre-adipocytes to
adhere, changing medium every 3-4 days until 80% confluent when the preadipocyte
will be passaged until 80% confluent (passage 1). At the end of passage 1
pre-adipocytes will be detached and frozen at 500,000 cells/mL in DMEM, 20% FBS,
10% dimethyl sulfoxide [DMSO, DLM-10RG-PK], 100 U/mL penicillin-streptomycin, and 2
mM L-Glutamine) and stored in liquid nitrogen for later analysis of pre-adipocyte
differentiation.
Cytokine quantitation will be carried out using magnetic bead multiple arrays
(Merck Millipore) on a MAGPIX® xPONENT 4.2 system or by commercial ELISA.
Adipose tissue vascularisation and fibrosis will be assessed on available frozen
biopsies embedded in OCT. Cryosections (10µm) will be immunostained using anti-CD31
to identify blood vessels. Blood vessel density will be calculated as the ratio of
blood vessel number to total section area. Adipose tissue fibrosis will be assessed
using picosirius red and Image J analysis.
Adipocytes will be stained with MitoTracker Green FM and MitoTracker Red, according
to manufacturer's instructions, and imaged using fluorescence microscopy in the BHF
GCRC Imaging Suite. Images will be analysed to assess mitochondrial morphology
(interconnectivity, size and swelling) using Mitomorph software. Adipocyte
mitochondria content will also be assessed after JC-1 staining as fluorescence
intensity per cell in a Cellometer. Mitochondrial content will be confirmed using
the independent method of mtDNA/nuclear DNA ratio using MT-CO2, MT-CYB, PPARG and
UCP1 expression by Taqman RT-PCR.
Mitochondrial fission/fusion will be estimated by quantifying the expressions of
genes/proteins involved in mitochondrial fission (DNM1L) and fusion (MFN1, MFN2 and
RHOT1) using Taqman RT-PCR and western blotting.
Gene and protein expression of mitochondrial respiratory complex and fatty acid
oxidation proteins will be carried out using Taqman RT-PCR and western blotting
respectively.
Blood sample analysis Plasma will be separated and frozen in aliquots at -80
degrees Celsius. Plasma adipokine (e.g. adiponectin, visfatin) levels will be
measured using commercial ELISA, as per standard product protocols.
Clinical management of patients in the study There will be no changes to patients'
clinical management as part of this study.
Assessment of safety Definitions of Adverse Events Adverse Events (AEs) and Serious
Adverse Events (SAEs) are defined as per the International Conference on
Harmonisation Good Clinical Practice (ICH-GCP) glossary of terms.
Adverse Events Needle punctures for blood and adipose tissue sampling do not cause
any serious problems for most patients. There is a small risk that needle punctures
may cause dizziness, discomfort, bleeding, bruising, or infections at the site.
Recording and reporting of Adverse Events Any untoward medical occurrence in a
patient involved in the study related to sample collection will be recorded and
reported in accordance with the Research Governance Framework (i.e. annually for
AEs and within 15 days for SAEs). Any SAE which is unexpected and related to the
sample collection will be reported to the Research Ethics Committee within 15 days
of the Chief Investigator becoming aware of the event. A summary of AEs and SAEs
will be provided to the Research Ethics Committee and the Research & Development
Office, NHS GGC, annually. The AEs and SAEs will be collected in the case report
forms during the period of the study.
Data Collection & Management Direct access to source data/documents Patient
specific information will be accessed from the electronic patient data management
system (IntelliSpace Critical Care and Anesthesia, Phillips Medical Systems) and
from the Clinical Portal electronic patient record. Access to these data systems
for the purpose of the study will be limited to appropriately delegated members of
the study team. Access by internal or external auditors will be managed in
accordance with the relevant Standard Operating Procedures of the Glasgow Clinical
Research Facility.
Data centre All identifiable data collected within the NHS Greater Glasgow and
Clyde (NHS GGC) will remain within NHS GGC. Only anonymised data and tissue samples
will be shared with the University of Glasgow.
All tissue samples will be processed and analysed at the University of Glasgow
School of Cardiovascular and Metabolic Health (SCMH), and surplus samples
bio-banked. The bio-banked tissue samples and associated data will be stored and
used in accordance with the policies of the SCMH.
Data Access Requests to access the data generated in this study should be made to
the Chief Investigator, and will be considered on an individual case-by-case basis,
and will be discussed with the Sponsor.
Data Retention Data will be retained for 5 years following completion of the study
and will remain the responsibility of the Chief Investigator.
Quality assurance During and/or after completion of the study, quality assurance
officers named by NHS GGC or the regulatory authorities may wish to perform onsite
audits. The Principal Investigator will be expected to cooperate with any audit and
to provide assistance and documentation (including source data) as requested.
Statistics Sample size A total of 60 patients will be recruited, with 30 patients
undergoing emergency surgery, and 30 patients who have been admitted to a critical
care unit. (as detailed under Study design above).
The inflammatory function of adipose tissue has not been examined in human tissue
in patients with sepsis in critical care. Previous work found significant
differences in adipocyte insulin resistance, adipokine secretion and genes
expression between pre-eclampsia patients and healthy pregnancy with n=13 patients
per group (36,37). Unpublished data comparing subcutaneous adipocyte
differentiation between age and BMI-matched European and South Asian men found an
PPARγ effect size of 0.72 (calculated using GPower). Assuming the study might find
a similar effect size between sepsis patients and controls, the investigators
require n=25 participants to detect a similar level of difference in gene
expression with 80% power. Accordingly, the investigators anticipate n=30 patients
per group will be sufficient to show significant differences in adipocyte function
for the proposed study, allowing for some incomplete analyses.
Description of statistical methods The primary outcome will be analysed using a
2-way ANOVA mixed model. Independent variables will be the presence or absence of
sepsis, and the adipose tissue depot sampled (subcutaneous and visceral). The
dependent variable will be quantity of cytokine secreted. The investigators will
include covariates in the model that are known to influence adipose tissue
distribution and function such as age, gender, BMI and, where available, ratio of
SAT:VAT (as a measurement of adipose tissue distribution).
For analyses in which both SAT and VAT are not available, populations will be
compared using two-sample t-tests where data is normally distributed (or can be
transformed to achieve this) or the Mann Whitney u-test if non-parametrically
distributed.
Level of significance to be used A p-value of <0.05 will be considered
statistically significant. All secondary analyses will be purely exploratory and
should be interpreted as hypothesis-generating.
Ethics & Clinical Governance Ethical approval This protocol and any amendments will
be submitted to the Scotland A Research Ethics Committee (REC), with the authority
to review studies requiring approval under the Adults with Incapacity (Scotland)
Act 2000. A copy of the documented decision of the REC will be available to the
sponsor and appropriate Research & Development (R&D) offices at each of the sites
for their formal approval of the study. Only sites which have been granted ethics
approval through the site-specific assessment, and R&D management approval will be
allowed to initiate the study.
Statement of compliance This study will adhere to the principles of the Data
Protection Act and the General Data Protection Regulations (GDPR), The Declaration
of Helsinki, and all relevant guidelines and legislation governing clinical
research. The investigators are responsible for the conduct of the study in
accordance with the principles of the International Conference on Harmonisation
Good Clinical Practice (ICH-GCP) guidelines (www.ich.org). All members of the study
team will be required to have completed GCP training.
Informed consent The vulnerability of this study group is fully appreciated, and
every effort will be undertaken to protect their safety and well-being. In line
with the applicable regulatory requirements and to comply with the Research
Governance Framework, consenting processes will be standardised and a robust
Standard Operating Procedure for consenting patients will be adhered to. The first
contact will be by clinical staff caring for the patient.
Patient confidentiality To maintain confidentiality, all case report forms (CRFs),
study reports and communication regarding the study will identify the patients by
the assigned unique study identifier and initials only. Patient confidentiality
will be maintained at every stage and data will not be made publicly available to
the extent permitted by the applicable laws and regulations.
Sponsorship This study will be sponsored by NHS Greater Glasgow & Clyde Research &
Innovation.
